Lixisenatide is a GLP-1 receptor agonist; in the ELIXA trial of 6,068 people with type 2 diabetes and a recent acute coronary event, it neither raised nor lowered major cardiovascular events against placebo over a median 25 months.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Lixisenatide is a GLP-1 receptor agonist; in the ELIXA trial of 6,068 people with type 2 diabetes and a recent acute coronary event, it neither raised nor lowered major cardiovascular events against placebo over a median 25 months. · pmid:26630143
In a 12-month phase 2 trial in 156 people with early Parkinson's disease, daily lixisenatide kept motor disability scores stable while they worsened by about 3 points on placebo. · pmid:38598572
Proportion of the 2 claims about Lixisenatide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Lixisenatide yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. · pmid 26630143 · 2015
Observational evidence· resolved human data at the emerging tier: thin, or contested
Trial of Lixisenatide in Early Parkinson's Disease. · pmid 38598572 · 2024
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.